Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients

被引:16
|
作者
Perrone, Valentina [1 ]
Cattaneo, Dario [1 ]
Radice, Sonia [1 ]
Sangiorgi, Diego [2 ]
Federici, Augusto B. [3 ]
Gismondo, Maria Rita [4 ]
Medaglia, Massimo [5 ]
Micheli, Valeria [4 ]
Vimercati, Stefania [5 ]
Pallone, Enza [6 ]
Esposti, Luca Degli [2 ]
Clementi, Emilio [1 ,7 ]
机构
[1] Univ Milan, L Sacco Univ Hosp, Dept Biomed & Clin Sci, Unit Clin Pharmacol, Milan, Italy
[2] CliCon Srl, Hlth Econ & Outcomes Res, Ravenna, Italy
[3] L Sacco Univ Hosp, Hematol & Transfus Med, Dept Clin Sci & Community Hlth, Milan, Italy
[4] L Sacco Univ Hosp, Clin Microbiol Virol & Diag Bioemergency, Milan, Italy
[5] L Sacco Univ Hosp, Pharmaceut Dept, Milan, Italy
[6] L Sacco Univ Hosp, Qual Clin Risk & Accreditat Unit, Milan, Italy
[7] IRCCS Eugenio Medea, Sci Inst, Bosisio Parini, Lecco, Italy
关键词
human immunodeficiency virus; therapeutic drug monitoring; health care costs;
D O I
10.2147/CEOR.S58036
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Highly active antiretroviral therapy (HAART) has reduced morbidity and mortality in patients infected with human immunodeficiency virus (HIV). Studies have documented high interindividual variability in the pharmacokinetics of antiretroviral drugs, which may impair the success of HAART if not managed properly. Therapeutic drug monitoring (TDM) is a useful diagnostic tool that helps clinicians to optimize drug doses so that drug concentrations associated with the highest therapeutic efficacy are obtained with a reduced risk of concentration-dependent adverse effects. The aim of this study was to assess whether use of TDM improves clinical outcomes and cost of illness. Methods: A retrospective cohort study was conducted at L Sacco University Hospital in Milan, Italy, in HIV-infected patients aged $18 years with at least one prescription of antiretroviral drugs for which TDM was applied. The inclusion period was from January 2010 to December 2011, with a follow-up period of up to 12 months. Laboratory and administrative databases were analyzed and matched with each other. Results: The cohort consisted of 5,347 patients (3,861 males and 1,486 females) of mean age 43.9 +/- 12.5 years. We found that TDM had been used in 143 of these patients, among whom adherence with therapy was significantly higher than among those in whom TDM had not been used (94% versus 78%). In TDM-controlled patients, the mean length of HIV-related hospitalization stay and mean cost of hospitalization were significantly reduced with respect to those observed in the group in which TDM had not been used (7.21days versus 29.47days and is an element of 293 versus is an element of 688, respectively). Conclusion: Inclusion of TDM as part of routine clinical optimization of drug dosing in HIVinfected patients is associated with higher adherence to therapy, reduced length of hospitalization stay, and reduced cost of illness.
引用
收藏
页码:341 / 348
页数:8
相关论文
共 9 条
  • [1] Outcomes of IBD patients treated with infliximab: The impact of therapeutic drug monitoring in real-life clinical practice
    Kamperidis, N.
    Middleton, P.
    Tyrrell, T.
    Stasinos, I.
    Arebi, N.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S394 - S394
  • [2] Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study
    Deconinck, Laurene
    Robineau, Olivier
    Valette, Michel
    Choisy, Philippe
    Bocket, Laurence
    Meybeck, Agnes
    Ajana, Faiza
    BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [3] Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study
    Laurène Deconinck
    Olivier Robineau
    Michel Valette
    Philippe Choisy
    Laurence Bocket
    Agnes Meybeck
    Faiza Ajana
    BMC Infectious Diseases, 19
  • [4] Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus
    Chan, KS
    Revicki, DA
    EVALUATION & THE HEALTH PROFESSIONS, 1998, 21 (02) : 265 - 281
  • [5] Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus
    Evy Yunihastuti
    Fhadilla Amelia
    Arini Ika Hapsari
    Bramantya Wicaksana
    Veritea Natali
    Alvina Widhani
    Andri Sanityoso Sulaiman
    Teguh Harjono Karjadi
    Health and Quality of Life Outcomes, 19
  • [6] Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus
    Yunihastuti, Evy
    Amelia, Fhadilla
    Hapsari, Arini Ika
    Wicaksana, Bramantya
    Natali, Veritea
    Widhani, Alvina
    Sulaiman, Andri Sanityoso
    Karjadi, Teguh Harjono
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2021, 19 (01)
  • [7] Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4
    Lang, Sylvie
    Mary-Krause, Murielle
    Cotte, Laurent
    Gilquin, Jacques
    Partisani, Marialuisa
    Simon, Anne
    Boccara, Franck
    Costagliola, Dominique
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (14) : 1228 - 1238
  • [8] Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
    Tsai, Mao-Song
    Chang, Sui-Yuan
    Lin, Shu-Wen
    Kuo, Ching-Hua
    Sun, Hsin-Yun
    Wu, Bin-Ru
    Tang, Sue-Yo
    Liu, Wen-Chun
    Su, Yi-Ching
    Hung, Chien-Ching
    Chang, Shan-Chwen
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2017, 50 (06) : 789 - 797
  • [9] Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting A retrospective cohort study
    Jacobson, Karen
    Ogbuagu, Onyema
    MEDICINE, 2018, 97 (43)